ONYX PHARMACEUTICALS INC
S-8, EX-5.1, 2000-10-18
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: ONYX PHARMACEUTICALS INC, S-8, 2000-10-18
Next: ONYX PHARMACEUTICALS INC, S-8, EX-23.1, 2000-10-18



<PAGE>


                                                                     Exhibit 5.1

                         [Cooley Godward LLP Letterhead]

October 18, 2000

ONYX Pharmaceuticals, Inc.
3031 Research Drive
Richmond, CA 94806

Ladies and Gentlemen:

You have requested our opinion with respect to certain matters in connection
with the filing by ONYX Pharmaceuticals, Inc. (the "Company"), a Delaware
corporation, of a Registration Statement on Form S-8 (the "Registration
Statement") with the Securities and Exchange Commission covering the offering of
up to 550,000 shares of the Company's Common Stock, par value $.001 per share
(the "Shares"), of which 400,000 shares are issuable pursuant to the Company's
1996 Equity Incentive Plan, as amended (the "Plan"), 75,000 shares are issuable
pursuant to the 1996 Non-Employee Directors' Stock Option Plan, as amended (the
"Directors' Plan"), and 75,000 shares are issuable pursuant to the Employee
Stock Purchase Plan, as amended (the " Purchase Plan").

In connection with this opinion, we have examined the Registration Statement and
related Prospectus, your Amended and Restated Certificate of Incorporation and
By-laws, and such other documents, records, certificates, memoranda and other
instruments as we deem necessary as a basis for this opinion. We have assumed
the genuineness and authenticity of all documents submitted to us as originals,
the conformity to originals of all documents submitted to us as copies thereof,
and the due execution and delivery of all documents where due execution and
delivery are a prerequisite to the effectiveness thereof.

On the basis of the foregoing, and in reliance thereon, we are of the opinion
that the Shares, when sold and issued in accordance with (i) the Plan, the
Directors' Plan or the Purchase Plan, as applicable, and (ii) the Registration
Statement and related Prospectus, will be validly issued, fully paid, and
nonassessable (except as to shares issued pursuant to certain deferred payment
arrangements, which will be fully paid and nonassessable when such deferred
payments are made in full).

We consent to the filing of this opinion as an exhibit to the Registration
Statement.

Very truly yours,

Cooley Godward LLP

By:      /s/ ROBERT L. JONES
         ------------------------
         Robert L. Jones


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission